Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.

Waller H, Chatterji U, Gallay P, Parkinson T, Targett-Adams P.

J Virol Methods. 2010 May;165(2):202-10. doi: 10.1016/j.jviromet.2010.01.020. Epub 2010 Feb 2.

PMID:
20132841
2.

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA.

J Hepatol. 2010 Jul;53(1):50-6. doi: 10.1016/j.jhep.2010.01.041. Epub 2010 Apr 3.

3.

Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.

Fernandes F, Ansari IU, Striker R.

PLoS One. 2010 Mar 23;5(3):e9815. doi: 10.1371/journal.pone.0009815.

4.

A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.

Yang F, Robotham JM, Grise H, Frausto S, Madan V, Zayas M, Bartenschlager R, Robinson M, Greenstein AE, Nag A, Logan TM, Bienkiewicz E, Tang H.

PLoS Pathog. 2010 Sep 23;6(9):e1001118. doi: 10.1371/journal.ppat.1001118.

5.

Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Rosnoblet C, Fritzinger B, Legrand D, Launay H, Wieruszeski JM, Lippens G, Hanoulle X.

J Biol Chem. 2012 Dec 28;287(53):44249-60. doi: 10.1074/jbc.M112.392209. Epub 2012 Nov 14.

6.

The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.

Hopkins S, Bobardt M, Chatterji U, Garcia-Rivera JA, Lim P, Gallay PA.

Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97. doi: 10.1128/AAC.00693-12. Epub 2012 May 14.

7.

Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.

Nag A, Robotham JM, Tang H.

J Virol. 2012 Dec;86(23):12616-24. doi: 10.1128/JVI.01351-12. Epub 2012 Sep 12.

8.

Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.

Chatterji U, Bobardt MD, Lim P, Gallay PA.

J Gen Virol. 2010 May;91(Pt 5):1189-93. doi: 10.1099/vir.0.018531-0. Epub 2010 Jan 27.

9.

Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.

Madan V, Paul D, Lohmann V, Bartenschlager R.

Gastroenterology. 2014 May;146(5):1361-72.e1-9. doi: 10.1053/j.gastro.2014.01.055. Epub 2014 Jan 31.

PMID:
24486951
10.

Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Yang F, Robotham JM, Nelson HB, Irsigler A, Kenworthy R, Tang H.

J Virol. 2008 Jun;82(11):5269-78. doi: 10.1128/JVI.02614-07. Epub 2008 Apr 2.

11.

A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.

Grisé H, Frausto S, Logan T, Tang H.

J Virol. 2012 May;86(9):4811-22. doi: 10.1128/JVI.06641-11. Epub 2012 Feb 15.

12.

Interactions of the Disordered Domain II of Hepatitis C Virus NS5A with Cyclophilin A, NS5B, and Viral RNA Show Extensive Overlap.

Ngure M, Issur M, Shkriabai N, Liu HW, Cosa G, Kvaratskhelia M, Götte M.

ACS Infect Dis. 2016 Nov 11;2(11):839-851. Epub 2016 Oct 5.

PMID:
27676132
13.

HCV NS5A and IRF9 compete for CypA binding.

Bobardt M, Hopkins S, Baugh J, Chatterji U, Hernandez F, Hiscott J, Sluder A, Lin K, Gallay PA.

J Hepatol. 2013 Jan;58(1):16-23. doi: 10.1016/j.jhep.2012.08.007. Epub 2012 Aug 15.

14.

Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex.

Liu Z, Yang F, Robotham JM, Tang H.

J Virol. 2009 Jul;83(13):6554-65. doi: 10.1128/JVI.02550-08. Epub 2009 Apr 22.

15.

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.

Foster TL, Gallay P, Stonehouse NJ, Harris M.

J Virol. 2011 Jul;85(14):7460-4. doi: 10.1128/JVI.00393-11. Epub 2011 May 18.

17.

Cyclophilin inhibitors for the treatment of HCV infection.

Fischer G, Gallay P, Hopkins S.

Curr Opin Investig Drugs. 2010 Aug;11(8):911-8. Review.

PMID:
20721833
18.

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J.

PLoS One. 2010 Oct 27;5(10):e13687. doi: 10.1371/journal.pone.0013687.

19.

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T.

Hepatology. 2009 Nov;50(5):1638-45. doi: 10.1002/hep.23281.

PMID:
19821520
20.

Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A.

Verdegem D, Badillo A, Wieruszeski JM, Landrieu I, Leroy A, Bartenschlager R, Penin F, Lippens G, Hanoulle X.

J Biol Chem. 2011 Jun 10;286(23):20441-54. doi: 10.1074/jbc.M110.182436. Epub 2011 Apr 13.

Supplemental Content

Support Center